Please assess the completion status of the following clinical trial:

Trial Title: Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-70.~* Patients with H.pylori infection (Positive for rapid urease test or 13C/14C-urea breath test).~* Patients who have never received H. pylori eradication treatment.~Exclusion Criteria:~* Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%.~* Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial.~* Patients with active gastrointestinal bleeding.~* Patients with a history of upper gastrointestinal surgery.~* Patients allergic to treatment drugs.~* Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks~* Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse~* Patients who are unwilling or incapable to provide informed consents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tid group (Type: EXPERIMENTAL): Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 20mg bid
- Qid group (Type: ACTIVE_COMPARATOR): Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 20mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).